Publications by authors named "A Askanase"
Background: Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). We aimed to determine the efficacy, safety, and tolerability of four doses of cenerimod in adults with moderate-to-severe SLE receiving standard of care background therapy.
View Article and Find Full Text PDFArticle Synopsis
- High-dose glucocorticoid (GC)-based treatments for lupus nephritis are common but can cause significant side effects and are not always fully effective; this study explored the impact of adding voclosporin to a low-dose GC regimen.* -
- Participants were matched from two study groups: those receiving voclosporin with low-dose GCs and mycophenolate mofetil (MMF), and those on high-dose GCs with MMF and intravenous cyclophosphamide (IVC); safety and efficacy were evaluated over 6 months.* -
- Results indicated that the voclosporin group experienced fewer adverse events and achieved better reductions in urine protein levels compared to those receiving high-dose GCs
Article Synopsis
- The Manhattan Lupus Surveillance Program (MLSP) investigated cardiovascular disease events in systemic lupus erythematosus (SLE) patients and compared their rates to population controls based on sex, age, and race/ethnicity.
- In a study of 1,285 SLE patients, 13.9% experienced cardiovascular events, with higher risks associated with being male and over the age of 60.
- The study found that Hispanic/Latino and non-Hispanic Black patients had significantly elevated risks for cardiovascular events compared to other racial groups, highlighting a higher overall prevalence of these events among SLE patients compared to the general population.
Background: Disease remission or low disease activity are key treatment targets for patients with systemic lupus erythematosus (SLE). Pivotal trials of belimumab were conducted before the introduction of these targets. In this study, we aimed to pool data across trials to assess attainment of remission and low disease activity in a large, racially and culturally diverse patient population with SLE.
View Article and Find Full Text PDFArticle Synopsis
- - This review evaluates modern treatments for systemic lupus erythematosus (SLE) based on a 2022 definition of disease modification: minimizing disease activity while reducing treatment toxicity and organ damage.
- - Analyzing data from 32 clinical trials and 54 observational studies covering 14 different SLE medications, the authors set criteria to assess treatment effectiveness over time, focusing on non-renal activity and organ damage.
- - Key findings show that while eight out of 14 treatments demonstrated potential for disease modification up to five years, only belimumab consistently met all criteria, with hydroxychloroquine suggesting long-term benefits, highlighting a need for further research on other therapies.